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Title: 
Intratympanic steroid for Menière’s disease: a systematic review 
Abstract 
Objectives To investigate the beneficial effects and safety of intratympanic steroid installation 
compared with placebo in patients with Menière's disease.  
Methods We performed a systematic literature search in MEDLINE and EMBASE for existing 
systematic reviews and individual randomized controlled trials (RCTs). Studies were included if 
they investigated the usage intratympanic steroids in patients aged 18 and above, with definite or 
probable Menière's disease. The quality of the identified existing reviews was assessed using the 
AMSTAR tool. The risk of bias in RCTs were assessed using the Cochrane Risk of Bias Tool and 
overall quality of the individual outcomes were evaluated using the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) method. 
Results The literature search provided four systematic reviews, from which one yielded a sufficient 
AMSTAR evaluation and subsequently provided three RCTs relevant for inclusion. Due to the lack 
of sufficient reporting of the data, quantitative synthesis was not applicable. In the qualitative 
synthesis for the primary outcome, the results from the RCTs showed that there was a slight 
indication of steroid treatment reducing the frequency of vertiginous attacks. No serious adverse 
events were reported. Based on the GRADE approach the quality for both findings is very low. No 
studies reported on the secondary outcomes.  
Conclusion The effect of intratympanic steroid treatment in Menière’s disease is questionable. 
There is a great need for further research to sufficiently assess whether steroid treatment may be 









The diagnosis of Menière’s disease is based on characteristic episodic unilateral symptoms with 2 
spontaneous vertigo spells combined with fluctuating low frequency sensorineural hearing loss, 3 
tinnitus and aural fullness. The Barany Society published new diagnostic criteria for Menières 4 
disease in 2015[1], but the diagnosis is still based on the clinical symptoms without a gold-standard 5 
test to confirm the diagnosis. Endolymphatic hydrops is considered a hallmark in Menières 6 
disease[2] and it has often been proposed that Menières disease is an immune-mediated 7 
endolymphatic sac disorder[3]. This has prompted the use of steroids, in particular intratympanic 8 
steroid treatment. Intratympanic steroid is believed to pass the blood-labyrinth barrier and reach the 9 
perilymph primarily through the membrane of the round window, but also via the lacunar mesh 10 
surrounding the labyrinth and the oval window membrane[3]. The concentration of steroid within 11 
the perilymph has been estimated to be 260 times higher following intratympanic installation 12 
compared to oral administration[4].  13 
Nevertheless, the true etiology of Menières disease remains uncertain[5]. Consequently, physicians 14 
and patients face a broad variety of treatment options, e.g. lifestyle and dietary recommendations, 15 
medical treatment with betahistin or diuretics, intratympanic gentamicin, and surgery. Surgical 16 
treatment modalities include endolymphatic sac surgery, neurectomy of vestibular neurotomy or 17 
labyrinthectomy and are usually reserved as last resort treatments[6, 7]. However, regardless of the 18 
treatment, the auditory and vestibular deficits generally progress over time[8]. An international 19 
consensus paper on the treatment of Menières disease was published in 2018 from six experts on 20 
Menières disease, which recommended intratympanic steroid as a second step treatment 21 
modality[7]. This is also the case in the recent European position statement paper on diagnosis and 22 
treatment of Menière’s disease [6]. Treatment with intratympanic steroids has become very popular 23 
during the last two decades, as it is easy to administer even in an office setup [6]. This review aims 24 
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to systematically identify, summarize and critically appraise the current evidence concerning the 25 
usage of intratympanic steroid in the treatment of patients (≥18 years of age) with definite or 26 
probable Menière’s disease. Specifically, we sought to evaluate the effects of intratympanic steroid 27 
treatment on frequency and duration of vertigo, serious adverse events, vestibular function as well 28 
as quality of life, impact on daily life, tinnitus and hearing loss.  29 
 30 
 Methods 31 
This work was performed in accordance with the guidelines of the Cochrane Collaboration and 32 
PRISMA [9]. A PRISMA checklist can be found in the supplementary information figure 1. The 33 
study protocol was registered in PROSPERO (CRD42018104113). 34 
This review is a part of a larger guideline on Menière’s disease published by the Danish Health 35 
Authority in 2018[10]. 36 
 37 
Literature search 38 
We performed an electronic systematic literature search in two steps. First, a search for systematic 39 
reviews was performed on December 19th 2017, with no restrictions to publication date, in order to 40 
identify relevant primary studies to be included in the synthesis. Secondly, a search was performed 41 
to identify individual randomized controlled trials (RCTs), where we limited the initiation date of 42 
the search to the dates after the latest search in the systematic reviews. Thus, the search for RCTs 43 
was performed on February 6th 2018 in EMBASE and MEDLINE databases. The search strategy 44 
was developed using medical subject heading (MeSH) and text words related to our eligibility 45 
criteria, i.e. Meniere, Menieres, Meniere disease/syndrome (English), Menieres sygdom/syndrome 46 
(Danish), Menieres sykdom (Norwegian), Menieres sjukdom (Swedish). There were no restrictions 47 
on the search in regards to publication status, however the search was limited to literature written in 48 
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English, Danish, Norwegian and Swedish. Search protocols are provided in the supplementary 49 
information figure 2.  50 
The selection of studies was based on the Population, Intervention, Comparison and Outcome 51 
(PICO) framework[11], with the following structure: Population: Inclusion criteria consisted of 52 
studies including patients aged 18 or above, with definite or probably Menière's disease as defined 53 
by Bárány Society 2015[1] or the American Academy of Otolaryngology–Head and Neck Surgery 54 
(AAO-HNS) criteria from 1995[12].  Exclusion criteria were studies including patients with a 55 
vertigo diagnosis other than Menière's disease and studies not applying diagnostic criteria that 56 
matched the above-mentioned diagnostic criteria. Intervention and Comparison: We included 57 
randomized controlled trials (RCT) investigating the usage of intratympanic steroid treatment 58 
compared to patients receiving placebo. Outcome: The primary outcomes included the frequency 59 
of vertigo attack(s) and serious adverse events as assessed at a minimum of three month following 60 
initial treatment. Secondary outcomes included hearing loss, tinnitus reduction, quality of life, 61 
impact on daily life, vestibular function, frequency of vertigo, and length of vertigo attack(s). The 62 
effect on tinnitus and duration of the vertigo attack was assessed three months following the initial 63 
treatment. The remaining secondary outcomes were assessed at the longest follow-up time 64 
(minimum one year after initial treatment). Frequency of vertigo and duration of attacks at the 65 
longest follow-up time (minimum one year following the initial treatment) was also included as a 66 
secondary outcome measure.  67 
 68 
Study selection  69 
The results of the literature search were imported to RefWorks, (Review Manager Software, version 70 
5.2, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) [13] 71 
duplicate references were removed, and the remaining records were imported into Covidence 72 
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software (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia) 73 
[14] for the screening process and data management. Title and abstract of potential studies were 74 
screened by one reviewer (LD) in order to assess if they meet the inclusion criteria as described 75 
above. The initial selection of studies was assessed by an additional reviewer (HEC). Subsequently, 76 
the full texts on potential studies were screened by two review authors (LD and BD) for eligibility. 77 
Disagreement was resolved through discussion or by consultation of a third reviewer (HEC). 78 
Neither of the review authors were blinded to the journal titles, study authors/institutions or year of 79 
publication. A flow chart was created and used to document the number of studies identified, 80 
selected and excluded. 81 
 82 
Quality assessment and critical appraisal of the evidence 83 
The quality of the included systematic reviews was assessed using the AMSTAR tool [15], to 84 
ensure methodological rigidity of the reviews that we based our subsequent search upon. 85 
For the critical appraisal of the individual RCTS, the Cochrane risk of bias tool[16] was applied 86 
including the following characteristics: randomization sequence generation; treatment allocation 87 
concealment; blinding of patients and personnel; blinding of outcome assessors; completeness of 88 
outcome data; selective outcome reporting; other sources of bias.  89 
Quality assessments of the individual outcomes of interest were subsequently evaluated using 90 
GRADE method [17], with the four possible ratings of the quality: high, moderate, low and very 91 
low. Downgrading was done, by investigating the following domains; risk of bias; inconsistency; 92 
indirectness; imprecision and publication bias. The overall quality of evidence was based on the 93 
lowest quality of the primary outcome. 94 
 95 
Data extraction  96 
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Two review authors (LD and HEC) independently extracted data and assessed risk of bias for the 97 
included RCTs in Covidence. Data extraction of the studies included the population demographics 98 
and baseline characteristics, details on intervention and control conditions, study design, outcome 99 
and time of measurement, as well as risk estimates. Discrepancies was identified and resolved 100 
through discussion. Following data extraction, all demographic data was exported to Review 101 
Manager [13].  102 
 103 
Statistical analysis and summary of findings 104 
It was not possible to perform the intended statistical analysis and summary of findings as described 105 
in our protocol, due to heterogenic reporting style and lack of data in the individual studies included 106 
in this review. Thus, the effect on individual outcomes and overall quality assessment were solely 107 
narratively described. Only the data that was available in the respective studies was used. Authors 108 
of the included studies were not contacted for further information. 109 
 110 
Results  111 
In the search for systematic reviews, we identified 122 records. Following a check for duplicates 112 
and none-relevant references, we identified seven systematic reviews that were obtained in full 113 
length and read thoroughly. Of these, four systematic reviews [3, 18-20] matched our clinical 114 
question, including a high quality Cochrane review containing one relevant RCT[21]. The 115 
remaining three reviews of low to high quality did not contribute with any further studies. The 116 
AMSTAR assessment of the four systematic reviews can be found in the supplementary 117 
information figure 3.  A search for primary studies based on the search date from the Cochrane 118 
review (which in this case was the 13th of January 2011) [3], identified 194 references that after the 119 
screening and selection process were reduced to two RCT matching the inclusion criteria[22, 23]. 120 
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Subsequently the total amount of evidence in this review is based on three RCT with a total of 121 
number of 220 patients[21-23]. A flowchart with reasons for exclusion can be seen in figure 1. 122 
 123 
The population in the included studies consisted of patients aged 18-84 years, all with unilateral 124 
definite Meniere disease in accordance to the diagnoses criteria of AAO-HNS 1995. In all the 125 
studies, the intervention was treatment with intratympanic dexamethasone compared to placebo. In 126 
the studies of Lambert 2012[23] and Lambert 2016[22], the intervention investigated was OTO-127 
104, which consists of a heat sensitive gel that solidified once reaching body temperature (dosage 128 
ranging from 3 mg/ml to 60 mg/ml). A further description of the included studies can be found in 129 
the supplementary information figure 4.  130 
 131 
Primary outcome 132 
The effect on the frequency of vertigo attack(s) was mentioned in two of the identified studies. In 133 
Lambert et 2012[23], 44 patients received a single injection of intratympanic OTO-104 at two 134 
different dosages (3mg/ml (n=14), 12mg/ml (n= 16)) or placebo (n= 14). The patients were 135 
observed for three months, and the frequency of vertigo was assessed as the fraction of days per 136 
month with definite vertigo. At three months, the 12 mg of OTO-104 led to the largest reduction in 137 
the frequency of vertigo (mean -0.211 ± SD 0.153), as compared to placebo (mean -0.124 ± SD 138 
0.153). This finding was not significant (p=0.086). In addition, there was no effect of 3mg OTO-139 
104 (mean -0.147 ± SD 0.166) on vertigo frequency as compared to placebo (p= 0.493). These 140 
findings are similar to the study of Lambert et al 2016[22], who found no effect on the rate of 141 
vertigo, three months following treatment with 60mg/ml OTO-104 as compared to placebo (mean 142 
change -0.052 (95% CI -0.108 - 0.004), p= 0.067). There were no serious adverse events observed 143 
in either of the two studies. The study of Anaya et al. [21] investigated the effect of 4mg/L 144 
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Dexamethasone on vertigo frequency and severity during a study period of two years. The authors 145 
report a decrease in the number of vertiginous spells during the course of the study (no analysis 146 
provided in the study). Furthermore, the authors found a significant reduction in vertigo severity in 147 
the group receiving dexamethasone as compared to placebo (90% versus 42%, p<0.001) measured 148 
by the Functional Level Scale from AAO-HNS 1995.  Anaya et al did not report on serious adverse 149 
events.  150 
 151 
Secondary outcome: 152 
Lambert et al 2012 assessed the effect on tinnitus via the tinnitus handicap inventory (THI) (total 153 
score), and found a reduction at three months (Mean change -12.2, -15.0 and -4.0 following 3mg, 154 
12, mg and placebo, respectively (no statistical analysis was provided in the study)). Quality of life 155 
was measured by the Menière’s disease Patient oriented Symptom-severity Index (MDPOSI), from 156 
which no effect was found (no data provided in the study). In addition, there were no clinically 157 
meaningful changes in hearing at all frequencies (no data provided in the study). Lambert et al 2016 158 
reports that the THI as well as frequency of tinnitus remained stable throughout the study period (no 159 
data provided in the study). Quality of life was measured through the SF-16 (16-item short-form 160 
health survey). Here, OTO-104 did not have an effect on the highest domain of the SF-16 as 161 
compared to placebo (mean 2.78 versus 1.20 (no statistical analysis provided in the study)), yet 162 
there was a significant effect at three months on certain subscales in the group receiving OTO-104 163 
as compared to placebo. These subscales included bodily pain (mean 3.01 versus 0.29, p= 0.039), 164 
vitality (mean 2.53 versus -0.35, p= 0.045) and social functioning (mean 3.52 versus 0.16, p= 165 
0.025). 166 
 Anaya et al. investigated pure tone average hearing, and found no significant change at a two-year 167 
follow-up, as the dexamethasone group had a mean hearing threshold of 53.4 dBHL, and the 168 
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placebo group a mean hearing threshold of 56 dBHL (no statistical analysis provided in the study). 169 
In addition, the impact on daily life was assessed through the dizziness handicap inventory (DHI), 170 
on which dexamethasone had statistical effect two years following the initiation of treatment as 171 
compared to placebo (mean 8.3 versus 23.7, p<0.008). 172 
There were no studies assessing the effect on the duration of vertigo attacks three months following 173 
initial treatment. In addition, neither vestibular function nor quality of life was reported at the 174 
longest follow-up (minimum one year after initiating treatment). 175 
 176 
Quality assessment and critical appraisal of the evidence 177 
Overall, the critical appraisal as assessed using the Cochrane risk of bias tool revealed that the 178 
random sequence generation and allocation concealment was unclear across all three studies, due to 179 
inadequate description. There was low risk of bias for the remaining risk of bias domains. An 180 
overview of the risk of bias assessment can be seen in figure 2. 181 
In accordance to the GRADE approach, this serious risk of bias due unclear sequence generation 182 
and allocation concealment combined with serious imprecision due to few patients in single studies, 183 
led to the overall quality of the individual outcome being very low.  184 
 185 
Discussion  186 
Based on the evidence from the evidence included in this review, there is still a lack of solid 187 
confirmation that intratympanic corticosteroid treatment has a positive effect in Menière’s disease.  188 
According to GRADE, the quality of evidence was very low for the individual outcomes 189 
investigating the effect of intratympanic corticosteroid in patients aged 18 and above, with definite 190 
or probably Menière's disease. The results were based on very few patients, which diminished the 191 
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precision and power of the estimates. In addition, there was risk of bias and inadequate reporting of 192 
outcome data. 193 
The chosen primary outcome was frequency of vertigo. Garduno-Anaya et al. [21] displayed the 194 
results on frequency of vertigo in a box-plot figure. However, there is no additional data or 195 
information on whether or not there is a statistically significant difference between the treatment 196 
and placebo group. Garduno-Anaya et al. reported a statistically significant reduction in the severity 197 
of vertigo measured with functional level scale and class A (complete control of vertigo) 24 months 198 
following initial treatment in the treatment group compared to the placebo group. The two 199 
remaining studies from Lambert et al 2012 and Lambert et al 2016 [22, 23] originate from the same 200 
research group. In contrast to Garduno-Anaya et al. they used OTO-104, a suspension of 201 
dexamethasone in a buffered gelatin in order to achieve a sustained release of dexamethasone. 202 
However, neither of these two studies was able to demonstrate a statistically significant effect of 203 
OTO-104 compared to placebo on the primary outcome frequency of vertigo. Nevertheless, they did 204 
report a positive effect in favor of intratympanic treatment with OTO-104 in some of the subscales 205 
(bodily pain, vitality and social functioning) in the quality of life questionnaire. None of the studies 206 
reported of any serious adverse advents. In the light of these findings, it should be noted that the use 207 
of steroid treatment in Menieres disease and in particular the usage of OTO-104 is still in the 208 
investigational stage. In accordance, the Food and Drug Administration (FDA) in the United States 209 
approve neither OTO-104 nor any other intratympanic steroid treatments for Menière’s disease. It is 210 
off-label use in many counties.  211 
We identified four reviews [3, 18-20] in our systematic literature search. However, none of them 212 
included the same three studies as we did. The Cochrane review[3] only included Gurduno-Anaya 213 
et al.[21] Lagvigne et al. [19] included prospective randomized trials, but did not restrict it to trials 214 
that had included a placebo group. The natural history with fluctuations in symptoms over time 215 
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makes these study designs less favorable. Nevertheless, they included six studies in total but 216 
concluded that only one study [21] demonstrated a reduction in severity of vertigo from 217 
intratympanic steroid treatment. The review of Patel et al [24] included non-randomized studies and 218 
reported a beneficial effect of intratympanic steroid treatment on vertigo control in these study 219 
designs [24]. Non-randomized trials are not included in the current review due to the high risk of 220 
bias in these study designs, yet the discrepancy between this current review and Patel et al [24] 221 
indicates that more research is needed on the usage of intratympanic steroid in Menière’s disease. 222 
Furthermore, reviews that also includes both randomized and non-randomized trials followed by a 223 
direct comparison of effects as a consequence of study designs should be conducted. 224 
Research in effective treatment modalities for Menière’s decease has been challenged not only by 225 
the absence of known etiology but also by lack of consensus on the diagnostic criteria and on how 226 
to report outcome data. The inconsistency in reporting outcome data hinders the possibility to 227 
perform high quality meta-analysis. There is also a lack of consensus on the treatment protocol for 228 
applying intratympanic steroids that results in inhomogeneity in the treatment protocols in the 229 
published studies [6]. In order to facilitate collaboration and improve the quality of clinical studies, 230 
Bárány Society published new consensus diagnostic criteria in 2015 [1]. The standardization of the 231 
diagnostic criteria may in the future increase the amount of comparable research, which currently is 232 
lacking within this field. However, as it is demonstrated in this review it is also essential to reach an 233 
international consensus on how to report outcome data.  234 
 235 
Strengths and limitations related to this systematic review 236 
Our systematic review were performed using transparent methods and a priori defined criteria in 237 
accordance with the guidelines of the Cochrane Collaboration and PRISMA, including protocol 238 
registration, comprehensive search and duplicate study selection, data extraction and quality 239 
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assessment. Limitations included a restricted search in language and study design, as this particular 240 
review was restricted to randomised controlled trials. Furthermore, two of included studies 241 
investigate the usage of a novel treatment method for the application of steroid treatment that is 242 
investigational and therefore not widely used. The authors of the included studies were not 243 
contacted for further information and thus the results are solely based on the published data.  244 
 245 
Conclusion 246 
There is still a need for high quality research to determine the effectiveness of intratympanic 247 
steroids in the treatment of Menière’s disease. Based on current evidence from RCT-studies, the 248 
effect of intratympanic steroid treatment in Menière’s disease is questionable. However, other study 249 
types beyond RCT designs have indicated an effect of intratympanic steroids in patients with 250 
Menière’s disease. Thus, it is not possible to rule out that there might be a beneficial effect linked to 251 
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Figure legends 306 
Figure 1: Flowchart showing the process of selecting a) systematic reviews and b) primary studies. 307 
Number of included studies and reason for exclusion is provided. 308 
Figure 2: Risk of bias assessment as assessed by the Cochrane risk of bias tool. A plus (+) indicates 309 
low risk of bias; a question mark (?) indicates unclear risk of bias and a minus (-) indicates high risk 310 
of bias. The specific type of bias is presented in the top column, and the individual studies in the left 311 
row.  312 
 313 
 314 
